Incretins and cardiovascular disease: to the heart of type 2 diabetes?

Major cardiovascular outcome trials and real-life observations have proven that glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs), regardless of structural GLP-1 homology, exert clinically relevant cardiovascular protection. GLP-1RAs provide cardioprotective benefits through glycaemic and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetologia 2023-10, Vol.66 (10), p.1820-1831
Hauptverfasser:	Solini, Anna, Tricò, Domenico, Del Prato, Stefano
Format:	Artikel
Sprache:	eng
Schlagworte:	Agonists Arteriosclerosis Blood pressure Body weight loss Cardiovascular diseases Clinical trials Diabetes Diabetes mellitus (non-insulin dependent) GLP-1 receptor agonists Glucagon Glucagon-like peptide 1 Heart diseases Homology Human Physiology Inflammation Insulin secretion Internal Medicine Kidney diseases Medicine Medicine & Public Health Metabolic Diseases Review
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!